Michael Kirschfink focuses on Complement system, Immunology, Factor H, CD46 and Alternative complement pathway. His work in Complement system addresses subjects such as Endocrinology, which are connected to disciplines such as Platelet. His work on Complement, C1-inhibitor, Atypical hemolytic uremic syndrome and Complement components as part of general Immunology research is frequently linked to Nafamostat mesylate, thereby connecting diverse disciplines of science.
His Factor H research is multidisciplinary, incorporating elements of Complement factor I, Borrelia burgdorferi and Microbiology. His CD46 research is multidisciplinary, incorporating perspectives in Decay-accelerating factor, Complement factor B and Complement membrane attack complex. His Alternative complement pathway research incorporates themes from Membranoproliferative glomerulonephritis and Internal medicine.
Michael Kirschfink mainly investigates Immunology, Complement system, Complement, Antibody and Internal medicine. His study in Alternative complement pathway, Classical complement pathway, Factor H, Complement membrane attack complex and CD59 is carried out as part of his Complement system studies. His Classical complement pathway research includes themes of Biochemistry and Complement receptor.
His Factor H study combines topics in areas such as Complement factor I, Borrelia burgdorferi, Microbiology and CD46. His study looks at the intersection of Complement and topics like Cancer research with Gene silencing. His studies in Internal medicine integrate themes in fields like Gastroenterology, Endocrinology and Pathology.
His primary scientific interests are in Immunology, Complement system, Internal medicine, Eculizumab and Complement. His Immunology study often links to related topics such as Disease. As part of one scientific family, Michael Kirschfink deals mainly with the area of Complement system, narrowing it down to issues related to the Ophthalmology, and often Age related and Downregulation and upregulation.
He combines subjects such as Gastroenterology, Complement factor I, Surgery and Oncology with his study of Internal medicine. His biological study spans a wide range of topics, including Nephrology, Factor H, Belatacept, Monoclonal and Atypical hemolytic uremic syndrome. His study explores the link between Complement and topics such as Cell biology that cross with problems in Apoptosis, Cell mediated immunity and Membrane.
Michael Kirschfink mostly deals with Immunology, Complement system, Atypical hemolytic uremic syndrome, Eculizumab and Complement factor I. His Immunology research focuses on Alternative complement pathway, Hereditary angioedema, C1-inhibitor, Classical complement pathway and Autoantibody. His work carried out in the field of Complement system brings together such families of science as Complement and Cell biology.
The Eculizumab study combines topics in areas such as Monoclonal, Internal medicine, Hypogammaglobulinemia, Catastrophic antiphospholipid syndrome and Immunoadsorption. His Complement factor I study combines topics from a wide range of disciplines, such as Endocrinology, Factor H, Macular degeneration and Glaucoma. Michael Kirschfink works mostly in the field of Factor H, limiting it down to topics relating to C3-convertase and, in certain cases, Molecular biology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease): An Update
Gerald B. Appel;H. Terence Cook;Gregory Hageman;J. Charles Jennette.
Journal of The American Society of Nephrology (2005)
Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.
Z Fishelson;N Donin;S Zell;S Schultz.
Molecular Immunology (2003)
Eculizumab in severe Shiga-toxin-associated HUS.
Anne-Laure Lapeyraque;Michal Malina;Véronique Fremeaux-Bacchi;Tobias Boppel.
The New England Journal of Medicine (2011)
Eculizumab for atypical hemolytic-uremic syndrome.
Jens Nürnberger;Thomas Philipp;Oliver Witzke;Anabelle Opazo Saez.
The New England Journal of Medicine (2009)
Immune evasion of Borrelia burgdorferi by acquisition of human complement regulators FHL-1/reconectin and Factor H.
Peter Kraiczy;Christine Skerka;Michael Kirschfink;Volker Brade.
European Journal of Immunology (2001)
Complement Resistance of Borrelia burgdorferi Correlates with the Expression of BbCRASP-1, a Novel Linear Plasmid-encoded Surface Protein That Interacts with Human Factor H and FHL-1 and Is Unrelated to Erp Proteins
Peter Kraiczy;Jens Hellwage;Christine Skerka;Heiko Becker.
Journal of Biological Chemistry (2004)
Complement in human diseases: Lessons from complement deficiencies.
Marina Botto;Michael Kirschfink;Paolo Macor;Matthew C. Pickering.
Molecular Immunology (2009)
Complement resistance of tumor cells: basal and induced mechanisms.
K Jurianz;S Ziegler;H Garcia-Schüler;S Kraus.
Molecular Immunology (1999)
Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II)
C. Licht;S. Heinen;M. Józsi;I. Löschmann.
Kidney International (2006)
Controlling the complement system in inflammation
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: